(NASDAQ: JAZZ) Jazz Pharmaceuticals's forecast annual revenue growth rate of 8.96% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 114.69%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.4%.
Jazz Pharmaceuticals's revenue in 2026 is $4,157,833,000.On average, 20 Wall Street analysts forecast JAZZ's revenue for 2026 to be $278,547,291,744, with the lowest JAZZ revenue forecast at $245,855,659,336, and the highest JAZZ revenue forecast at $305,648,533,480. On average, 19 Wall Street analysts forecast JAZZ's revenue for 2027 to be $300,848,089,316, with the lowest JAZZ revenue forecast at $264,996,670,876, and the highest JAZZ revenue forecast at $338,097,105,424.
In 2028, JAZZ is forecast to generate $327,949,331,052 in revenue, with the lowest revenue forecast at $285,656,810,316 and the highest revenue forecast at $382,880,995,916.